Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an…
GA Depot
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
Recommended Posts
- Disrupted brain blood flow tied to poorer cognitive function in MS
- FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS
- More than 3 million people living with MS globally, report shows
- Learning to listen as I wage a never-ending, silent battle with chronic pain
- Experimental therapy K-9 restores lost vision and mobility in MS mice